Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

NCT02644369 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02644369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02644369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 21, 2016
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, epithelial ovarian cancer, malignant melanoma, squamous cell cancer of head and neck, triple negative breast cancer